There are well-established disparities in cancer incidence and outcomes by race/ethnicity
that result from the interplay between structural, socioeconomic, socio-environmental …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Lung cancer is nowadays among the most prevalent diseases worldwide and features the
highest mortality rate among various cancers, indicating that early diagnosis of the disease …

Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint
blockade (ICB). The impact of TMB on outcomes with targeted therapies has not been …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …